Cargando…
Loading, please waitCargando…
Loading, please waitDecision Guide
A clear, side-by-side look at two regenerative tools used at our clinic in Cancún, México: platelet-rich plasma (PRP) and mesenchymal stem cell (MSC) therapy. What each one actually is, the goals each suits best, what the peer-reviewed trials show — and why, for many patients, the honest answer is not 'either/or' but a sequenced, physician-designed plan delivered under COFEPRIS oversight in Cancún.
PRP is your own concentrated platelets, delivering a burst of growth factors to one site. MSCs are living mesenchymal cells that signal whole-system repair through paracrine factors. At Regeneris in Cancún, México, a physician decides — case by case, under COFEPRIS oversight — whether PRP, MSCs, or a sequenced combination fits your diagnosis and goals.
Two different tools
Both PRP and stem cell therapy belong to regenerative medicine, but they work at completely different biological scales. PRP is a concentrate of your own blood platelets — autologous, prepared the same day. MSCs are living cells, multipotent and able to signal repair across an entire system. Understanding that distinction is the foundation of any honest comparison — and the reason the two are so often sequenced rather than treated as rivals. The published clinical literature on PRP preparation is heterogeneous enough that a JBJS systematic review explicitly called for standardization in how PRP is prepared and reported, which is why an evaluation in Cancún at Regeneris starts with what kind of preparation is appropriate, not a generic label.
Goals & conditions
There is meaningful overlap, especially in orthopedics, but each modality has a center of gravity. The lists below reflect where each tool tends to do its strongest work in physician practice — always confirmed case-by-case in a medical evaluation in Cancún, never assumed from a symptom or a label alone.
Side by side
The practical differences patients ask about most — where each comes from, how it works, how soon you feel something, how long it lasts, how mature the evidence is, and what safety looks like. No prices appear here: every Regeneris protocol is individualized, with a personalized written quote issued only after a free medical evaluation in Cancún, México.
| Dimension | PRP | Stem cells (MSC) |
|---|---|---|
| Source | Autologous — your own blood, drawn the same visit and spun in a clinical centrifuge. | Autologous (your own marrow/adipose) or allogeneic (donor-screened cord-tissue Wharton's jelly), expanded in a certified lab. |
What the research shows
"Regenerative" is not one evidence category. Within both PRP and MSC therapy, some uses rest on randomized controlled trials while others are still preclinical or early-phase. An honest comparison reports that gradient rather than implying every application is equally established. The notes below summarize the published picture — none of it guarantees an individual outcome, and your physician in Cancún matches the modality to the strength of evidence for your specific case.
A 2017 systematic review in JBJS of the clinical orthopedic literature concluded that the way PRP is prepared and reported across studies is so inconsistent it limits comparison of results. The authors explicitly called for standardization in protocols and composition reporting — a key reason a Cancún physician documents which preparation you receive, rather than relying on the label 'PRP' alone.
The 2021 RESTORE randomized trial (288 adults with mild-to-moderate knee OA) compared intra-articular PRP to saline placebo and found no significant difference in pain or medial tibial cartilage volume at 12 months. The finding does not invalidate PRP as a tool — but it tempers blanket claims and is why we frame PRP as one option, not a guaranteed fix.
Sequencing & cadence
When PRP and stem cells are used in the same patient, order and timing are deliberate — not a fixed package. The logic below describes how a physician in Cancún may reason about sequencing; specific intervals, doses, and whether to combine at all are individualized in your evaluation and stated in your written plan.
For mild, focal soft-tissue injuries or aesthetic goals, a physician may start with PRP — an autologous, lower-burden option — and reassess at 6–12 weeks. If the response is good, no further escalation may be needed.
If the disease is multi-site, more advanced, or the PRP response was partial or short-lived, the plan may escalate to MSC therapy — systemic or local — because MSC effects act on the regenerative environment as a whole, not just one injection site.
Safety in depth
Both modalities are generally well tolerated under qualified supervision, but each carries situations where therapy should be deferred or only undertaken with specialist input. This is general safety information, not personal advice — disclose every medication, supplement, and diagnosis to your physician in Cancún so you can be screened properly.
Better together (when indicated)
The framing of 'PRP vs stem cells' is useful for learning the difference — but in practice the strongest plans often use both, in deliberate order. Because PRP delivers a focal, short-burst signal and MSCs reshape the broader regenerative environment, the two can be layered for a result neither achieves alone.
Many physician plans start with PRP for a focal complaint and only escalate to MSC therapy if the response is partial — a stepwise approach that respects the principle of using the lightest effective tool first.
Decision framework
A practical way to reason about PRP, stem cells, or both — before you ever sit down with a physician in Cancún.
One tendon or joint, mild-to-moderate, points toward PRP first. Multi-site disease or a goal of whole-system regeneration points toward MSC therapy.
Mild grades often respond to PRP; more advanced grades (e.g. knee OA Grade III) or longer-standing disease often warrant MSC consideration based on the published clinical signal.
Some PRP indications are extensively studied; others have mixed or negative trial signals. MSC therapy has a randomized signal in knee OA and is investigational elsewhere. A physician matches the modality to the evidence for your specific situation.
Frequently the answer is yes. The final call — PRP, MSCs, or both, and in what order — comes from your medical evaluation in Cancún, not from a webpage.
FAQ
The questions patients in Cancún ask us most when weighing PRP against stem cell therapy.
PRP (platelet-rich plasma) is a concentrate of your own blood platelets, drawn and prepared the same day and re-injected at one site. Stem cells — specifically mesenchymal stem cells (MSCs) — are living, multipotent cells that signal repair across an entire system through paracrine factors. PRP delivers a short, local burst of growth factors; MSCs reshape a broader regenerative environment. They are complementary tools, not the same therapy, and a physician at Regeneris in Cancún decides which fits your case.
This page is informational and does not constitute medical advice. Both PRP and stem cell therapies are investigational for many indications, and outcomes vary by patient, condition, preparation, and protocol. The choice between — or sequencing of — these modalities is a medical decision that requires an individualized evaluation with a licensed physician; disclose all current medications and conditions. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your goals, recent labs, and any imaging. A physician at Regeneris in Cancún, México will review your case and tell you honestly whether PRP, stem cells, or a sequenced plan fits — with a personalized written quote after your free medical evaluation.
Put simply: PRP delivers a short, local burst of your own growth factors to one site. Stem cells release signaling molecules that can reshape an entire regenerative environment. They are complementary tools — not the same therapy — and at Regeneris in Cancún, México the choice between them is medical, not commercial.
| Mechanism |
|---|
| Local growth-factor burst — PDGF, TGF-β, VEGF, IGF-1, EGF released by activated platelets at the injection site. |
| Paracrine signaling — secreted exosomes, growth factors, and cytokines that modulate inflammation and recruit local progenitor cells. |
| Scale | Focal — acts where it is injected, typically one site at a time. | Systemic or local — can reshape the whole regenerative environment or be injected at a target. |
|---|
| Onset | Days to a few weeks for the local effect; relief can build over a series. | Gradual — anti-inflammatory effects over weeks, tissue remodeling over 1–3 months. |
|---|
| Durability | Often months for the right indication, then may require repeat injection. | Tends to be longer-lasting per course; many orthopedic responses are measured in months. |
|---|
| Evidence maturity | Extensive literature in orthopedics; randomized trials show mixed results by indication and preparation. | Growing clinical literature with a randomized signal in knee OA; investigational for many other indications. |
|---|
| Safety & contraindications | Very favorable autologous profile; caution with active infection, anticoagulation, severe platelet disorders. | Well-documented profile from a certified lab chain; not for active malignancy or uncontrolled immunosuppression without specialist oversight. |
|---|
This table is a general orientation, not a prescription. Onset, durability, dose, preparation, and suitability all depend on your diagnosis, history, and goals — and are confirmed only in a physician evaluation in Cancún. Regeneris does not publish prices online; a personalized written quote follows a free medical evaluation.
Short, citation-ready definitions of the core terms on this page.
A randomized active-control trial in knee osteoarthritis reported improved pain and function with allogeneic bone-marrow MSCs versus a hyaluronic-acid comparator, supporting a durable orthopedic signal — while authors and regulators still classify the indication as investigational pending larger confirmatory trials.
The field's own founder reframed these cells as 'medicinal signaling cells,' arguing that their benefit comes chiefly from secreted, paracrine factors rather than from engraftment and tissue replacement — the mechanistic basis for most MSC protocols today and a key reason MSC effects tend to be broader and longer per course than a single PRP injection.
The practical takeaway: ask not "is it regenerative?" but "what is the evidence for this specific use, in a patient like me?" That question — and the honest answer — is exactly what a physician evaluation in Cancún is for.
Because MSC responses tend to be longer-lasting per course while PRP effects are often time-limited, follow-up determines whether a PRP booster is added, an MSC course is repeated, or the plan is adjusted — always under supervision in Cancún.
Why sequence matters: the rationale is to use the lightest effective tool first and escalate only when warranted. It is a medical decision, documented in your plan in Cancún, México — never a self-directed stack.
If any of the above applies to you, it does not automatically rule therapy out — it means the decision belongs with a physician in Cancún (and, where relevant, your specialist), not a webpage.
A patient pursuing systemic regeneration might receive an MSC infusion to reset the inflammatory environment, with a focal PRP injection added later at a specific tendon or joint that needs extra attention.
Combination is a medical decision. Sequencing, dosing, and whether to combine at all are determined by your physician in Cancún after evaluation — never a fixed package applied to everyone.
This is exactly how Regeneris designs care in Cancún, México: PRP and stem cells are tools in one integrated, physician-led plan — chosen, sequenced, or combined to fit your case.
It depends on severity and the published evidence. The 2021 RESTORE randomized trial in JAMA found that PRP did not significantly outperform saline placebo for pain or medial tibial cartilage volume in mild-to-moderate knee OA at 12 months. A separate randomized trial by Vega et al. (2015) reported clinical improvement with allogeneic bone-marrow MSCs versus a hyaluronic-acid comparator. Your physician in Cancún weighs your grade, imaging, and history against this evidence rather than treating PRP and MSCs as interchangeable.
Yes — and they often are, in deliberate sequence. A common pattern is to start with the lighter, focal tool (PRP) for a specific site and escalate to MSC therapy if the response is partial or the disease is more advanced. Or to reset the inflammatory environment with an MSC infusion and add a focal PRP touch-up later. Combination is always a medical decision in your evaluation in Cancún — never a self-directed stack.
Because PRP is not one product. A 2017 JBJS systematic review of the orthopedic literature concluded that PRP preparation and reporting are so heterogeneous across studies — leukocyte content, spin protocol, platelet concentration, activation status — that comparison is limited. That is one reason your physician in Cancún documents which preparation you receive and frames expectations accordingly, instead of treating 'PRP' as a single intervention with a single result.
PRP typically acts within days to a few weeks at the injection site, with the effect often peaking over a short series of injections. MSC effects are more gradual: anti-inflammatory changes build over weeks and tissue remodeling over one to three months, with responses that tend to be longer-lasting per course. The right comparison is not 'faster' in the abstract but which timeline fits your diagnosis — which a physician determines in evaluation in Cancún, México.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
The other major regenerative comparison — signaling peptides vs MSC therapy, and how they are often combined.